ArticleAsian Pacific journal of cancer prevention : APJCP2025
Serum Homocysteine and Its Diagnostic Significance in Oral Submucous Fibrosis: A Cross-Sectional Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral Submucous Fibrosis (OSMF) is a chronic, progressive, potentially malignant disorder of the oral cavity, predominantly associated with areca nut chewing. Oxidative stress and nutritional deficiencies, particularly of folate and vitamin B12, have been implicated in its pathogenesis. Homocysteine (Hcy), a sulfur-containing amino acid, serves as a sensitive biomarker for folate and B12 metabolism and is known to contribute to oxidative stress when elevated. This study aimed to evaluate the serum homocysteine levels in OSMF patients and assess its potential as a biochemical marker for disease severity and progression. MATERIALS AND
methodsA comparative study was conducted on 60 participants, including 30 clinically and histopathologically confirmed OSMF patients and 30 healthy age- and gender-matched controls. Serum homocysteine levels were estimated using ELISA. Clinical grading of OSMF was based on interincisal distance. Statistical analysis was performed using t-tests, ANOVA, and Receiver Operating Characteristic (ROC) curve analysis to determine the diagnostic utility of homocysteine levels.
resultsMean serum homocysteine levels were significantly higher in the OSMF group (24.17 µmol/L) compared to controls (10.80 µmol/L) (p < 0.001). ANOVA revealed a progressive increase in homocysteine levels across OSMF grades: Grade I - 19.05 µmol/L, Grade II - 23.65 µmol/L, Grade III - 28.92 µmol/L, and Grade IV - 36.98 µmol/L. ROC analysis showed an AUC of 1.00, with an optimal cut-off of 15.90 µmol/L yielding 100% sensitivity and specificity for distinguishing OSMF from controls.
conclusionElevated serum homocysteine levels are significantly associated with OSMF and correlate with disease severity. Homocysteine may serve as a promising, non-invasive biochemical marker for early detection and progression monitoring in OSMF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.